Citations

Clear

1825 citation(s) found for "Yu, Emily".

Mitigating and preventing perioperative opioid-related harm
Cohen, Jonathan , Balfanz, Greg, Methangkool, Emily , Harbell, Monica W. , Cohen, Jonathan

Mayo Clinic

Current Opinion in Anaesthesiology | September 9, 2024 | Volume: 37 | Issue: 6 | Pages: 697-704

10.1097/aco.0000000000001426 | PMID 39247993 Get It

Purpose of review Although necessary for treatment of acute pain, opioids are associated with significant harm in the perioperative period and further intervention is necessary perioperatively to mitigate opioid-related harm. Recent findings Opioid-naive patients are often first exposed to opioids when undergoing surgery, which can result in significant harm. Despite their benefits in reducing acute postsurgical pain, they are also associated with risks ranging from mild (e.g., pruritis, constipation, nausea) to potentially catastrophic (e.g. opioid-induced ventilatory impairment, respiratory depression, death). Overprescribing of opioids can lead to opioid diversion and drug driving. In this review, we will discuss opioid-related harm and what strategies can be used perioperatively to mitigate this harm. Interventions such as optimizing nonopioid analgesia, implementing Enhanced Recovery after Surgery programs, effective respiratory monitoring, patient education and opioid stewardship programs will be discussed. Summary We will review policy and guidelines regarding perioperative opioid management and identify challenges and future directions to mitigate opioid-related harm.
Better cardiovascular health is associated with slowed clinical progression in autosomal dominant frontotemporal lobar degeneration variant carriers
VandeBunte, Anna M. , Staffaroni, Adam M. , Yaffe, Kristine , Ramos, Eliana Marisa , Rascovsky, Katya, Wong, Bonnie , Domoto‐Reilly, Kimiko , Snyder, Allison , Pressman, Peter , Mendez, Mario F. , Fields, Julie A. , Darby, Ryan, Masdeu, Joseph C. , Pasqual, Maria Belen, Ghoshal, Nupur , Mackenzie, Ian R. , Heuer, Hilary W. , Kramer, Joel H. , Boxer, Adam L. , Forsberg, Leah K. , Rosen, Howard J., Casaletto, Kaitlin B. , Domoto-Reilly, Kimiko , Snyder, Allison , Lee, Hyun Woo , Paolillo, Emily W. , Hsiung, Ging‐Yuek Robin , Saloner, Rowan , Tartaglia, Maria Carmela , Knopman, David S. , Bozoki, Andrea C , Litvan, Irene , Galasko, Douglas , Masdeu, Joseph C , Honig, Lawrence S. , Appleby, Brian S. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2024 | Volume: 20 | Issue: 10 | Pages: 6820-6833

10.1002/alz.14172 | PMID 39240048 Get It

AbstractINTRODUCTIONCardiovascular health is important for brain aging, yet its role in the clinical manifestation of autosomal dominant or atypical forms of dementia has not been fully elucidated. We examined relationships between Life's Simple 7 (LS7) and clinical trajectories in individuals with autosomal dominant frontotemporal lobar degeneration (FTLD).METHODSTwo hundred forty‐seven adults carrying FTLD pathogenic genetic variants (53% asymptomatic) and 189 non‐carrier controls completed baseline LS7, and longitudinal neuroimaging and neuropsychological testing.RESULTSAmong variant carriers, higher baseline LS7 is associated with slower accumulation of frontal white matter hyperintensities (WMHs), as well as slower memory and language declines. Higher baseline LS7 associated with larger baseline frontotemporal volume, but not frontotemporal volume trajectories.DISCUSSIONBetter baseline cardiovascular health related to slower cognitive decline and accumulation of frontal WMHs in autosomal dominant FTLD. Optimizing cardiovascular health may be an important modifiable approach to bolster cognitive health and brain integrity in FTLD.Highlights Better cardiovascular health associates with slower cognitive decline in frontotemporal lobar degeneration (FTLD). Lifestyle relates to the accumulation of frontal white matter hyperintensities in FTLD. More optimal cardiovascular health associates with greater baseline frontotemporal lobe volume. Optimized cardiovascular health relates to more favorable outcomes in genetic dementia.
Trends in adverse effects of medical treatment in Paediatric populations in the United States: A global burden of disease study, 2000–2019
Fujiwara, Shintaro , Leibovitch, Emily , Nishimura, Yoshito , Woo, Russell , Bhagavathula, Akshaya Srikanth , Nishimura, Yoshito , Bhagavathula, Akshaya Srikanth , Harada, Ko , Otsuka, Fumio

Mayo Clinic

Paediatric and Perinatal Epidemiology | September 3, 2024 | Volume: 38 | Issue: 8 | Pages: 692-699

10.1111/ppe.13116 | PMID 39225176 Get It

AbstractBackgroundAdverse effects of medical treatment (AEMT) pose significant risks to paediatric patients. However, the mortality trends associated with AEMT in this population have been unclear.ObjectiveWe aimed to clarify the trends in the incidence, disability‐adjusted life years (DALYs) and mortality rates of AEMT for children in the US from 2000 to 2019.MethodsData were retrieved from the Global Burden of Disease study 2019. We estimated age‐standardized incidence, DALYs and mortality rates of paediatric AEMT per 100,000 children in the US using a Bayesian meta‐regression model. We also analysed incidence, DALYs and mortality in different age groups, and employed Joinpoint regression models to assess the age‐ and sex‐specific trends.ResultsThe number of deaths due to AEMT in children, the number of cases, and DALYs were 105.1, 551,076 and 145,555 in 2019, decreased by 37.5%, 6% and 28% from those in 2000, respectively. Age‐standardized mortality rates decreased across all age groups, while the incidence increased across all age groups with an average annual percentage change (AAPC) of 2.2% in those children <1 year and 4.5% in 5–9 years of age. The increases in DALYs over time was higher in children aged 1–4 years (AAPC: 0.51, 95% CI: 0.47, 0.62) and 5–9 years (AAPC: 0.33, 95% CI: 0.15, 0.50), with the 1–4 year age group being the highest.ConclusionThe study reveals declining AEMT mortality but rising incidence and DALYs, emphasizing a disproportionate burden in <1, 1–4 and 5–9 years. To develop effective mitigation strategies, future research is warranted to identify the causes of increased AEMT in children, especially young males.
Immobile Left Arm in a 2-month-old Infant
Hadley, J, Koti, Ajay , Johnson, Katie L. , Brown, Emily , Hadley, Julia C.

Mayo Clinic

Pediatrics in Review | September 1, 2024 | Volume: 45 | Issue: 9 | Pages: e33-e36

10.1542/pir.2023-006170 | PMID 39217125 Get It

Visual pathology reports for improved collaboration at multidisciplinary head and neck tumor board
Fassler, Carly , Yalamanchi, Pratyusha , Aweeda, Marina , Rezk, Julie, Whitaker, Ryan, Rigsby, Ryan K. , Aulino, Joseph M., Hosokawa, Emily, Mehrad, Mitra , Ely, Kim, Lewis, James S. , Derman, Evan, LaHood, Ed, Sinard, Robert J. , Rosenthal, Eben L , Topf, Michael C , Murphy, Barbara, Lockney, Natalie A. , Rohde, Sarah L. , Rosenthal, Eben L. , Topf, Michael C.

Mayo Clinic

Head & Neck | August 29, 2024 | Volume: 47 | Issue: 2 | Pages: 452-462

10.1002/hed.27926 | PMID 39206523 Get It

AbstractPurposeMultidisciplinary tumor boards (TB) are the standard for discussing complex head and neck cancer cases. During TB, imaging and microscopic pathology is reviewed, but there is typically no visualization of the resected cancer.MethodsA pilot study was conducted to investigate the utility of visual pathology reports at weekly TB for 10 consecutive weeks. Faculty‐level participants completed a pre‐survey and post‐survey to assess understanding of resected cancer specimens.ResultsProviders (n = 25) across seven medical specialties completed pre‐survey and post‐survey. Following intervention, providers reported significant improvement in understanding of anatomic orientation of the specimen and sites of margin sampling (mean 47.4–96.1, p < 0.001), ability to locate the site of a positive margin (mean 69.5–91.1, p < 0.001), and confidence in treatment plans created (mean 69.5–89.2, p < 0.001) with the addition of visual pathology reports.ConclusionsVisual pathology reports improve provider understanding of resected cancer specimens at multidisciplinary TB.
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Zayac, Adam , Bock, Allison M. , Nowakowski, Grzegorz S. , Ayers, Emily C. , Girton, Mark , Hu, Marie , Beckman, Amy , Li, Shaoying , Chang, Julie E , Sandoval‐Sus, Jose , Ansari‐Lari, M. Ali, Kothari, Shalin , Kress, Anna, Xu, Mina L. , Torka, Pallawi , Smith, Stephen D. , Naresh, Kikkeri N. , Karimi, Yasmin , Evens, Andrew M. , Naik, Seema , Kamdar, Manali , Haverkos, Bradley M. , Rubinstein, P , Chaudhry, Amina, Epperla, Narendranath , Zayac, Adam S , Bock, Allison M , Ayers, Emily C , Girton, Mark , Hu, Marie , Li, Shaoying , Medeiros, L Jeffrey , Chang, Julie E , Torka, Pallawi , Smith, Stephen D , Karimi, Yasmin H , Bond, David A , Naik, Seema G , Haverkos, Bradley M , Karmali, Reem , Farooq, Umar , Vose, Julie , Rubinstein, Paul G , Olszewski, Adam J , Evens, Andrew M , Naresh, Kikkeri N , Kamdar, Manali , Epperla, Narendranath , Landsburg, Daniel J. , Medeiros, L. Jeffrey , Kurt, Habibe , Sundaram, Suchitra , Bond, David A. , Karmali, Reem , Vose, Julie M. , Chaudhry, Amina, Olszewski, Adam J.

Mayo Clinic

Blood Advances | August 27, 2024 | Volume: 8 | Issue: 20 | Pages: 5355-5364

10.1182/bloodadvances.2024013791 | PMID 39189932 Get It

Abstract Little is known about the central nervous system (CNS) risk in high-grade B-cell lymphoma, not otherwise specified (HGBL NOS). Hence, we sought to describe the rates of baseline CNS involvement, risk of CNS recurrence after primary therapy, and management strategies in HGBL NOS. In this multicenter retrospective study, we included 160 adults with newly diagnosed HGBL NOS treated between 2016 and 2021 at 20 US institutions. Eleven patients (7%) had baseline CNS involvement at diagnosis (leptomeningeal = 6, parenchymal = 4, and both = 1). Baseline CNS involvement was significantly associated only with MYC rearrangement (OR = 3.5) and testicular (in men) or female pelvic (in women) involvement (OR = 8.1). There was no significant difference in survival outcomes between patients with HGBL NOS with (median PFS = 4 years) or without (median PFS = 2.4 years) baseline CNS involvement (P = 0.45). The cumulative incidence of CNS recurrence at 3 years was 11%. Patients with baseline CNS involvement were at the highest risk (48.5% vs 8% for those without baseline CNS involvement) and were excluded from the risk factors analysis for CNS recurrence. The risk for CNS recurrence was significantly associated with blood or bone marrow involvement, CD5 expression, non–germinal center B-cell subtype, and “dual-expresser lymphoma” phenotype, however, high CNS IPI was not. The prognosis of relapsed HGBL NOS was poor, regardless of whether recurrence was systemic or limited to the CNS, and with currently available salvage strategies, including autologous transplantation and chimeric antigen receptor T-cell modalities, almost all patients with CNS recurrence ultimately succumbed to their disease.
Piezo channels modulate human lung fibroblast function
Zheng, Mengning, Yao, Yang , Borkar, Niyati A. , Thompson, Michael A., Zhang, Emily , Drake, Li Y. , Ye, Xianwei , Vogel, Elizabeth R. , Pabelick, Christina M. , Prakash, Y. S. , Prakash, Y S , Drake, Li , Pabelick, Christina M , Zhang, Emily Y , Vogel, Elizabeth R , Thompson, Michael A.

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | August 27, 2024 | Volume: 327 | Issue: 4 | Pages: L547-L556

10.1152/ajplung.00356.2023 | PMID 39189800 Get It

The lung is an inherently mechanosensitive organ that can respond to mechanical forces in adaptive or maladaptive ways, including via remodeling resulting in increased fibrosis. We explored the mechanisms that link mechanical forces to remodeling using human lung fibroblasts. We found that mechanosensitive Piezo channels increase with stretch and mediate extracellular matrix formation and the fibroblast-to-myofibroblast transition that occurs with stretch. Our data highlight the importance of Piezo channels in lung mechanotransduction toward remodeling.
Surgical management of rare tumors (Part 1)
Stetson, Alyssa , Saluja, Saurabh , Cameron, Danielle B. , Mansfield, Sara A. , Polites, Stephanie F. , Dahl, John P. , Austin, Mary T., Aldrink, Jennifer H. , Christison‐Lagay, Emily , Aldrink, Jennifer H , Christison-Lagay, Emily R , Honeyman, Joshua N.

Mayo Clinic

Pediatric Blood & Cancer | August 26, 2024 | Volume: 72 | Issue: S2 | Pages: No page available

10.1002/pbc.31287 | PMID 39185712 Get It

AbstractWith an annual cumulative occurrence of approximately 15,000 in North America, all childhood cancers are rare. Very rare cancers as defined by both the European Cooperative Study Group for Rare Pediatric Cancers and the Children's Oncology Group fall into two principal categories: those so uncommon (fewer than 2 cases/million) that their study is challenging even through cooperative group efforts (e.g., pleuropulmonary blastoma and desmoplastic small round cell tumor) and those that are far more common in adults and therefore rarely studied in children (e.g., thyroid, melanoma, and gastrointestinal stromal tumor). Treatment strategies for these latter tumors are typically based on adult guidelines, although the pediatric variants of these tumors may harbor different genetic signatures and demonstrate different behavior. If melanoma and differentiated thyroid cancer are excluded, other rare cancer types account for only 2% of the cancers in children aged 0 to 14. This article highlights several of the most common rare tumor types.
Abusive Pediatric Burns Module in the Child Abuse Pediatrics Curriculum for Physicians (CAP-CuP)
Johnson, Katie L. , Crumm, Caitlin E. , Brown, Emily , Johnson, Katie

Mayo Clinic

MedEdPORTAL | August 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11429 | PMID 39184363 Get It

Artificial Intelligence Models Are Limited in Predicting Clinical Outcomes Following Hip Arthroscopy
Mehta, Apoorva , El-Najjar, Dany , Howell, Harrison J. , Gupta, Puneet , Arciero, Emily , Marigi, Erick M. , Parisien, Robert L. , Howell, Harrison , Trofa, David P , Marigi, Erick , El-Najjar, Dany B , Gupta, Puneet

Mayo Clinic

JBJS Reviews | August 23, 2024 | Volume: 12 | Issue: 8 | Pages: No page available

10.2106/jbjs.rvw.24.00087 | PMID 39172870 Get It

Background: Hip arthroscopy has seen a significant surge in utilization, but complications remain, and optimal functional outcomes are not guaranteed. Artificial intelligence (AI) has emerged as an effective supportive decision-making tool for surgeons. The purpose of this systematic review was to characterize the outcomes, performance, and validity (generalizability) of AI-based prediction models for hip arthroscopy in current literature. Methods: Two reviewers independently completed structured searches using PubMed/MEDLINE and Embase databases on August 10, 2022. The search query used the terms as follows: (artificial intelligence OR machine learning OR deep learning) AND (hip arthroscopy). Studies that investigated AI-based risk prediction models in hip arthroscopy were included. The primary outcomes of interest were the variable(s) predicted by the models, best model performance achieved (primarily based on area under the curve, but also accuracy, etc), and whether the model(s) had been externally validated (generalizable). Results: Seventy-seven studies were identified from the primary search. Thirteen studies were included in the final analysis. Six studies (n = 6,568) applied AI for predicting the achievement of minimal clinically important difference for various patient-reported outcome measures such as the visual analog scale and the International Hip Outcome Tool 12-Item Questionnaire, with area under a receiver-operating characteristic curve (AUC) values ranging from 0.572 to 0.94. Three studies used AI for predicting repeat hip surgery with AUC values between 0.67 and 0.848. Four studies focused on predicting other risks, such as prolonged postoperative opioid use, with AUC values ranging from 0.71 to 0.76. None of the 13 studies assessed the generalizability of their models through external validation. Conclusion: AI is being investigated for predicting clinical outcomes after hip arthroscopy. However, the performance of AI models varies widely, with AUC values ranging from 0.572 to 0.94. Critically, none of the models have undergone external validation, limiting their clinical applicability. Further research is needed to improve model performance and ensure generalizability before these tools can be reliably integrated into patient care. Level of Evidence: Level IV . See Instructions for Authors for a complete description of levels of evidence.